Mobile

A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001790-41

A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imatinib Studio prospettico, multicentrico, randomizzato, in aperto, con controllo attivo, a due gruppi paralleli, di fase III per confrontare l'efficacia e la sicurezza di masitinib versus sunitinib in pazienti affetti da tumori stromali gastrointestinali in progressione dopo trattamento con imatinib

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare efficacy of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor after progression with imatinib Comparare l’efficacia di masitinib 12 mg/kg/die versus sunitinib 50 mg/die nel trattamento di pazienti con tumore stromale gastrointestinale in progressione dopo trattamento con imatinib

Critère d'inclusion

  • Gastrointestinal stromal tumor after progression with imatinib,Tumori stromali gastrointestinali in progressione dopo trattamento con imatinib

Liens